PAX6 and type 2 diabetes mellitus: As beta cell loss is a hallmark of both T1D and T2D, we examined the potential participation of PAX6 in diabetes‐associated beta cell loss by treating EndoC‐βH1 cells with high glucose and palmitic acid (HGPA) to mimic the diabetic condition.